Association Between Migraine and Ischemic Cardio-Cerebrovascular Disease (CCVD) and Effects of Triptans and Ergotamine on the Risk of Ischemic CCVD in Patients with Migraine in the Korean NHIS-HEALS Cohort.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
03
07
2023
medline:
31
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Triptans and ergotamine are commonly used to treat migraine, a risk factor for ischemic stroke. This study aimed to investigate the association between migraine and ischemic cardio-cerebrovascular disease (CCVD). Further analyses were performed to examine whether symptom-relieving treatment of migraine with triptans and ergotamine reduces ischemic CCVD in migraineurs. Participants from the Korean NHIS-HEALS cohort database were divided into patients reporting headache without migraine (HA), migraineurs who received at least one prescription for triptans or ergotamine (TE), and migraineurs who were prescribed neither triptans nor ergotamine (NTNE). Ischemic CCVDs comprised ischemic cerebrovascular diseases and cardiovascular diseases. Using cox proportional hazards regression models, primary and secondary analysis for risk of ischemic CCVDs was compared. Among 62,272 patients diagnosed with migraine or HA, men with migraine or HA numbered 14,747 and 8935, respectively, while the numbers of women were 27,836 and 10,754, respectively. The median follow-up was 6.65 years. The overall incidence rate of CCVDs was 4728/38,590 (12.25%) in females and 3158/23,682 (13.33%) in males. Compared with the HA group, the hazard ratios (HRs) (95% CIs) of the TE and NTNE groups for ischemic CCVDs were 1.18 (1.01-1.39) and 1.39 (1.28-1.50), respectively, in males, and 1.22 (1.09-1.37) and 1.53 (1.42-1.65), respectively, in females, after full adjustment for confounding variables. Compared with the NTNE group, the HRs (95% CIs) of the TE group for ischemic CCVDs were 0.86 (0.73-0.999) in males and 0.80 (0.72-0.88) in females. Migraine increased the risk of ischemic CCVDs in both sexes, and migraineurs treated with triptans and ergotamine were at lower risk of ischemic CCVDs than migraineurs who did not take those medications, especially in women.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Triptans and ergotamine are commonly used to treat migraine, a risk factor for ischemic stroke. This study aimed to investigate the association between migraine and ischemic cardio-cerebrovascular disease (CCVD). Further analyses were performed to examine whether symptom-relieving treatment of migraine with triptans and ergotamine reduces ischemic CCVD in migraineurs.
METHODS
METHODS
Participants from the Korean NHIS-HEALS cohort database were divided into patients reporting headache without migraine (HA), migraineurs who received at least one prescription for triptans or ergotamine (TE), and migraineurs who were prescribed neither triptans nor ergotamine (NTNE). Ischemic CCVDs comprised ischemic cerebrovascular diseases and cardiovascular diseases. Using cox proportional hazards regression models, primary and secondary analysis for risk of ischemic CCVDs was compared.
RESULTS
RESULTS
Among 62,272 patients diagnosed with migraine or HA, men with migraine or HA numbered 14,747 and 8935, respectively, while the numbers of women were 27,836 and 10,754, respectively. The median follow-up was 6.65 years. The overall incidence rate of CCVDs was 4728/38,590 (12.25%) in females and 3158/23,682 (13.33%) in males. Compared with the HA group, the hazard ratios (HRs) (95% CIs) of the TE and NTNE groups for ischemic CCVDs were 1.18 (1.01-1.39) and 1.39 (1.28-1.50), respectively, in males, and 1.22 (1.09-1.37) and 1.53 (1.42-1.65), respectively, in females, after full adjustment for confounding variables. Compared with the NTNE group, the HRs (95% CIs) of the TE group for ischemic CCVDs were 0.86 (0.73-0.999) in males and 0.80 (0.72-0.88) in females.
CONCLUSIONS
CONCLUSIONS
Migraine increased the risk of ischemic CCVDs in both sexes, and migraineurs treated with triptans and ergotamine were at lower risk of ischemic CCVDs than migraineurs who did not take those medications, especially in women.
Identifiants
pubmed: 37460781
doi: 10.1007/s40261-023-01290-7
pii: 10.1007/s40261-023-01290-7
doi:
Substances chimiques
Ergotamine
PR834Q503T
Tryptamines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-550Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160. https://doi.org/10.1111/j.1468-2982.2003.00824.x .
Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA. 1989;261(15):2211–6.
doi: 10.1001/jama.1989.03420150061038
pubmed: 2926969
Stewart W, Wood C, Reed M, Roy J, Lipton R. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28(11):1170–8. https://doi.org/10.1111/j.1468-2982.2008.01666.x .
doi: 10.1111/j.1468-2982.2008.01666.x
pubmed: 18644028
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61. https://doi.org/10.1046/j.1468-2982.2002.00310.x .
doi: 10.1046/j.1468-2982.2002.00310.x
pubmed: 11993614
Lambert GA, Zagami AS. The mode of action of migraine triggers: a hypothesis. Headache. 2009;49(2):253–75. https://doi.org/10.1111/j.1526-4610.2008.01230.x .
doi: 10.1111/j.1526-4610.2008.01230.x
pubmed: 18793210
Loder E. Triptan therapy in migraine. N Engl J Med. 2010;363(1):63–70. https://doi.org/10.1056/NEJMct0910887 .
doi: 10.1056/NEJMct0910887
pubmed: 20592298
Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch NeurPsych. 1938;39(4):737–63.
doi: 10.1001/archneurpsyc.1938.02270040093005
Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83(3):271–80.
pubmed: 21302868
Edvinsson L. The Trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. https://doi.org/10.1111/head.13081 .
doi: 10.1111/head.13081
pubmed: 28485848
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–82. https://doi.org/10.1038/nrneurol.2010.127 .
doi: 10.1038/nrneurol.2010.127
pubmed: 20820195
Jacobs B, Dussor G. Neurovascular contributions to migraine: moving beyond vasodilation. Neuroscience. 2016;338:130–44. https://doi.org/10.1016/j.neuroscience.2016.06.012 .
doi: 10.1016/j.neuroscience.2016.06.012
pubmed: 27312704
González-Hernández A, Lozano-Cuenca J, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors. J Headache Pain. 2018;19(1):40. https://doi.org/10.1186/s10194-018-0869-8 .
doi: 10.1186/s10194-018-0869-8
pubmed: 29802544
pmcid: 5970131
Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330(7482):63. https://doi.org/10.1136/bmj.38302.504063.8F .
doi: 10.1136/bmj.38302.504063.8F
pubmed: 15596418
pmcid: 543862
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123(7):612–24. https://doi.org/10.1016/j.amjmed.2009.12.021 .
doi: 10.1016/j.amjmed.2009.12.021
pubmed: 20493462
pmcid: 2900472
McKinley EC, Lay CL, Rosenson RS, Chen L, Chia V, Colantonio LD, et al. Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults. J Headache Pain. 2021;22(1):1–13. https://doi.org/10.1186/s10194-021-01338 .
doi: 10.1186/s10194-021-01338
Tfelt-Hansen P, Saxena P, Dahlöf C, Pascual J, Lainez M, Henry P, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(1):9–18.
doi: 10.1093/brain/123.1.9
pubmed: 10611116
Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013;14(12):1659–67. https://doi.org/10.1517/14656566.2013.810209 .
doi: 10.1517/14656566.2013.810209
pubmed: 23786565
Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;2021: STR.0000000000000375. https://doi.org/10.1161/STR.0000000000000375 .
doi: 10.1161/STR.0000000000000375
Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(4):563–8. https://doi.org/10.1212/01.WNL.0000110312.36809.7F .
doi: 10.1212/01.WNL.0000110312.36809.7F
pubmed: 14981171
Ashok P, Kharche JS, Raju R, Godbole G. Metabolic equivalent task assessment for physical activity in medical students. Natl J Physiol Pharm Pharmacol. 2017;7(3):236.
Vargas BB, Dodick DW, Wingerchuk DM, Demaerschalk BM. Migraine with and without aura and risk for cardiovascular disease. Curr Atheroscler Rep. 2008;10(5):427–33. https://doi.org/10.1007/s11883-008-0065-4 .
doi: 10.1007/s11883-008-0065-4
pubmed: 18706284
Bigal M, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74(8):628–35. https://doi.org/10.1212/WNL.0b013e3181d0cc8b .
doi: 10.1212/WNL.0b013e3181d0cc8b
pubmed: 20147658
pmcid: 3462501
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009. https://doi.org/10.1136/bmj.b3914 .
doi: 10.1136/bmj.b3914
pubmed: 19861375
pmcid: 2768778
Nicolas S, Nicolas D. Triptans. StatPearls. Treasure Island: StatPearls Publishing; 2022.
Wammes-Van Der Heijden E, Rahimtoola H, Leufkens H, Tijssen C, Egberts A. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology. 2006;67(7):1128–34. https://doi.org/10.1212/01.wnl.0000240128.76399.fa .
doi: 10.1212/01.wnl.0000240128.76399.fa
pubmed: 17030745
Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31. https://doi.org/10.1177/0333102414550416 .
doi: 10.1177/0333102414550416
pubmed: 25246519
Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache J Head Face Pain. 2004;44(5):414–25. https://doi.org/10.1111/j.1526-4610.2004.04078.x .
doi: 10.1111/j.1526-4610.2004.04078.x
Edvinsson L, Uddman E, Wackenfors A, Davenport A, Longmore J, Malmsjö M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin Sci (Lond). 2005;109(3):335–42. https://doi.org/10.1042/CS20050016 .
doi: 10.1042/CS20050016
pubmed: 15853772
MaassenVanDenBrink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44:S13–9. https://doi.org/10.1111/j.1526-4610.2004.04104.x .
doi: 10.1111/j.1526-4610.2004.04104.x
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. https://doi.org/10.1038/s41572-019-0106-z .
doi: 10.1038/s41572-019-0106-z
pubmed: 31420554
Jiangping S, Zhe Z, Wei W, Yunhu S, Jie H, Hongyue W, et al. Assessment of coronary artery stenosis by coronary angiography: a head-to-head comparison with pathological coronary artery anatomy. Circ Cardiovasc Interv. 2013;6(3):262–8. https://doi.org/10.1161/CIRCINTERVENTIONS.112.000205 .
doi: 10.1161/CIRCINTERVENTIONS.112.000205
pubmed: 23696600
Elgendy IY, Nadeau SE, Bairey Merz CN, Pepine CJ. Migraine headache: an under-appreciated risk factor for cardiovascular disease in women. J Am Heart Assoc. 2019;8(22): e014546. https://doi.org/10.1161/JAHA.119.014546 .
doi: 10.1161/JAHA.119.014546
pubmed: 31707945
pmcid: 6915301
Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs. 2005;19(11):951–72. https://doi.org/10.2165/00023210-200519110-00005 .
doi: 10.2165/00023210-200519110-00005
pubmed: 16268666
Bigal ME, Golden W, Buse D, Chen YT, Lipton RB. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010;50(2):256–63. https://doi.org/10.1111/j.1526-4610.2009.01595.x .
doi: 10.1111/j.1526-4610.2009.01595.x
pubmed: 20039953
Alwhaibi M, Pan X, Sambamoorthi U. Triptan use for migraine headache among adults with cardiovascular risk. Value Health. 2014;17(3):A57–8. https://doi.org/10.1016/j.jval.2014.03.340 .
doi: 10.1016/j.jval.2014.03.340